Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15

Blood

Volumn 124, Issue 7, 2014, Pages 1081-1088

  Imamura, Masaru ^a   Shook, David ^b   Kamiya, Takahiro ^a   Shimasaki, Noriko ^a   Chai, Sally M H ^a   Coustan Smith, Elaine ^a   Imai, Chihaya ^c   Campana, Dario ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; CD8 ANTIGEN; CD8 ANTIGEN, ALPHA CHAIN; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; B CELL LYMPHOMA; BONE MARROW; BREAST CARCINOMA; CANCER CELL; CARCINOMA CELL LINE; CELL EXPANSION; CELL GROWTH; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; EWING SARCOMA CELL LINE; GENE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INTERLEUKIN 15 GENE; K562 CELL LINE; KIDNEY; LEUKEMIA; LEUKEMIA CELL; LIVER; LUNG; LYMPHOMA CELL; MOUSE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SIGNAL TRANSDUCTION; SOLID TUMOR; SPLEEN; TUMOR XENOGRAFT; U937 CELL LINE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD8; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-15; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905989882     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-556837     Document Type: Article

References (42)

1. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
2. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-819. (Pubitemid 36917769)
3. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-650. (Pubitemid 38020523)
4. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-4884. (Pubitemid 40807317)
5. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
6. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8): 3051-3057.
7. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-959.
8. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-49.
9. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010-4017.
10. Lapteva N, Durett AG, Sun J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14(9):1131-1143.
11. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligandmismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118(12):3273- 3279.
12. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287-6297.
13. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986;137(5):1735-1742. (Pubitemid 16014833)
14. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297-3302.
15. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180-190.
16. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13-25.
17. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996;4(4):329-336. (Pubitemid 26174048)
18. Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99(5):937-943. (Pubitemid 27123630)
19. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14-32. (Pubitemid 32061238)
20. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100(10):3633-3638. (Pubitemid 35303933)
21. Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009;114(12):2417-2426.
22. Sneller MC, Kopp WC, Engelke KJ, et al. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD81 T effector memory population in peripheral blood. Blood. 2011;118(26):6845-6848.
23. Waldmann TA, Lugli E, Roederer M, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011;117(18):4787-4795.
24. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17(5):537-547. (Pubitemid 35351500)
25. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol. 2004;173(6):3594-3598. (Pubitemid 39280717)
26. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD81 T cell homeostasis. J Exp Med. 2004;200(7):825-834. (Pubitemid 39362919)
27. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. 2005;105(2):721-727. (Pubitemid 40070758)
28. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-383. (Pubitemid 40967217)
29. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777-1786.
30. Musso T, Calosso L, Zucca M, et al. Human monocytes constitutively express membranebound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 1999;93(10):3531-3539. (Pubitemid 29220921)
31. Chertova E, Bergamaschi C, Chertov O, et al. Characterization and favorable in vivo properties of heterodimeric soluble IL-15-IL-15Ra cytokine compared to IL-15 monomer. J Biol Chem. 2013;288(25):18093-18103.
32. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419. (Pubitemid 28183370)
33. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell. 2009;138(5):838-854.
34. Miller JS. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program. 2013;2013:247-253.
35. Hsu C, Jones SA, Cohen CJ, et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood. 2007;109(12):5168-5177. (Pubitemid 46890533)
36. Lugli E, Goldman CK, Perera LP, et al. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood. 2010;116(17):3238-3248.
37. Mishra A, Liu S, Sams GH, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22(5):645-655.
38. Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17(6):700-707.
39. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28(28):4390-4399.
40. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287.
41. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009;145(5):606-613.
42. Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012;14(7):830-840.